5-chloro-2-methylsulfanylindan-1-one | 500770-95-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-chloro-2-methylsulfanylindan-1-one
• 英文别名: 5-chloro-2-methylsulfanyl-2,3-dihydroinden-1-one
• CAS: 500770-95-6
• 化学式: C₁₀H₉ClOS
• 分子量: 212.7
• InChiKey: KMMAMBBYPKHMOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-2-methylsulfanylindan-1-one 在 sodium periodate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 5-chloro-2-methanesulfinylindan-1-one
  参考文献：
  名称：

  Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity

  摘要：

  本发明实施例涉及减轻哺乳动物体重的方法，以及用于预防或治疗肥胖的方法，包括给予C2-取代的茚-1-酮体系及其生理上可接受的盐和生理功能衍生物。用于本发明实施例方法的化合物可能包括式1的化合物，其中基团如定义所示，以及它们的生理上可接受的盐。

  公开号：

  US20030134882A1
• 作为产物：
  描述：

  2-bromo-5-chloro-1-indanone 、 sodium thiomethoxide 在 silica gel 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以giving 5-chloro-2-methylsulfanylindan-1-one of melting point 90° C.的产率得到5-chloro-2-methylsulfanylindan-1-one
  参考文献：
  名称：

  C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  本发明实施例涉及C2取代的茚醇以及其生理上可接受的盐和生理上功能衍生物。本发明实施例的化合物可能包括式I1的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的过程。例如，这些化合物适用于用作食欲抑制剂。

  公开号：

  US20030114681A1

文献信息

• C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20030130345A1

  公开（公告）日：2003-07-10

  Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention include compounds of formula I 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.

  该发明的实施例涉及C2-取代的茚烷酮及其生理上可接受的盐和生理功能衍生物。该发明的实施例化合物包括式I1的化合物，其中基团如所定义，并其生理上可接受的盐以及其制备方法。这些化合物例如适用于作为厌食药使用。
• C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Dutschlan GmbH.

  公开号：US20030153609A1

  公开（公告）日：2003-08-14

  The present invention is directed C2-disubstituted indan-1-ones of the Formula I, 1 physiologically acceptable salts, and physiologically functional derivatives thereof, and pharmaceutical compositions comprising such compounds, salts and derivatives, which are useful for reducing weight, for the prophylaxis or treatment of obesity, and for the prophylaxis or treatment of type II diabetes in mammals. The invention is directed also to methods for reducing weight and such treatments and prophylaxis. The invention is directed also to processes for the preparation of such compounds.

  本发明涉及式I的C2-二取代的茚-1-酮，1生理上可接受的盐，及其生理上功能衍生物，以及包含这些化合物、盐和衍生物的制药组合物，这些组合物有助于减轻体重，预防或治疗哺乳动物的肥胖症和II型糖尿病的预防或治疗。本发明还涉及减轻体重、治疗和预防上述疾病的方法。本发明还涉及制备这些化合物的方法。
• Polysubstituted indan-1-ol compounds, and methods for their preparation and use
  申请人：——

  公开号：US20030105145A1

  公开（公告）日：2003-06-05

  Polysubstituted indan-1-ol compounds, methods for their preparation; and methods for their use are disclosed herein. In particular, the invention relates to polysubstituted indan-1-ol compounds of the formula I 1 and their physiologically acceptable salts. The compounds are useful, for example, as anorectics.

  本文披露了多取代的茚-1-醇化合物及其制备方法和使用方法。具体而言，本发明涉及公式I1的多取代的茚-1-醇化合物及其生理上可接受的盐。例如，这些化合物可用作厌食剂。
• Polysubstituted indan-1-ol- systems for the prophylaxis or treatment of obesity
  申请人：——

  公开号：US20030130323A1

  公开（公告）日：2003-07-10

  Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed 1 Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.

  公开了式I的多取代的indan-1-ol化合物，其生理上可接受的盐和生理上功能衍生物。本文还公开了包含该化合物的组合物，制备方法以及用于预防或治疗肥胖症的方法。
• C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
  申请人：——

  公开号：US20030181491A1

  公开（公告）日：2003-09-25

  The present invention is directed to C2-disubstituted indan-1-ol systems of the Formula I, 1 physiologically acceptable salts and physiologically functional derivatives thereof, and pharmaceutical compositions comprising such compounds, salts, and derivatives, which are useful for reducing weight, for the prophylaxis or treatment of obesity, and for the prophylaxis or treatment of type II diabetes in mammals. The invention is directed also to methods for reducing weight and such treatments and prophylaxis. The invention is directed also to processes for the preparation of such compounds.

  本发明涉及公式I中的C2-二取代的茚环-1-醇系统，1生理学上可接受的盐和生理功能衍生物，以及包含这些化合物、盐和衍生物的制药组合物，它们对于减轻体重、预防或治疗肥胖症以及预防或治疗哺乳动物的2型糖尿病是有用的。本发明还涉及减轻体重的方法以及这种治疗和预防方法。本发明还涉及制备这些化合物的方法。